復鋭醫療科技(01696.HK)正在英國建立直銷業務渠道
格隆匯6月15日丨復鋭醫療科技(01696.HK)公吿,公司正在英國建立直銷業務渠道。新的直銷業務渠道將以能量源設備業務作為起步,再逐步擴展到公司的美麗健康生態系統業務單元,例如個人護理、注射填充及美容牙科。
在戰略市場建立直銷業務渠道並直接專注於終端用户及客户是公司的長期戰略之一,而公司將英國視為執行發展戰略及構建全球美麗健康生態系統的優質戰略市場。
公司相信,建立新的直銷渠道將使公司能夠更高效率及更有效地響應產品性能及客户反饋、與終端用户建立真誠關係及客户忠誠度,並加強公司在英國的品牌形象及產品競爭力,其將有利於公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.